CRISPR Casgevy Revenue Hits $116M in 2025 as Patient Initiations Triple
CRISPR Therapeutics reported $54M in Casgevy revenue in Q4 and $116M for 2025, treating 147 patients globally, nearly tripling initiations year-over-year, with reimbursement covering roughly 90% of U.S. eligible individuals. The company ended 2025 with $1.98B cash and saw R&D expenses rise to $83.5M as net loss widened to $130.6M.
1. Casgevy Uptake
Casgevy generated $54M in fourth-quarter revenue and $116M for the full year after 64 infusions in Q4 and 147 first cell collections in 2025, nearly triple the prior year. U.S. reimbursement now covers roughly 90% of eligible patients, with access also secured across Europe and the Middle East, including Scotland.
2. Financial Performance
CRISPR Therapeutics closed 2025 with $1.98B in cash and marketable securities. R&D spending rose to $83.5M in Q4, while the net loss expanded to $130.6M versus $37.3M a year earlier, reflecting increased clinical and commercial investment.
3. Pipeline Progress
The in vivo liver editing program CTX310 is in Phase 1b for lipid disorders and CTX321 is in enabling studies with data due in H2 2026. The siRNA candidate CTX611 is in Phase 2 for surgical patients, and Zugo-cel is advancing in autoimmune and oncology trials in combination with pirtobrutinib.